Overview

Efficacy and Safety of HS-25 or in Combination With Atorvastatin in Chinese Adults With Primary Hypercholesterolemia

Status:
Unknown status

Trial end date:
2019-05-28

Target enrollment:

Participant gender:

Summary

To determine the efficacy of the HS-25 (10mg or 20mg) or in combination with Atorvastatin (10mg)in reducing low density lipoprotein-cholesterol (LDL-C) levels after a 12-week period of treatment in adults with primary hypercholesterolemia; To determine the safety of HS-25 (10mg or 20mg) or in combination with Atorvastatin (10mg)in subjects with LDL-C after a 40-week period of treament.

Phase:

Phase 3

Details

Lead Sponsor:

Zhejiang Hisun Pharmaceutical Co. Ltd.

Treatments:

Atorvastatin
Atorvastatin Calcium